Treating Malignant Melanoma through an emerging therapy.

Immunotherapy has been showing a great potential in treating skin cancer like Malignant Melanoma (MM). It is a state of malignancy which arises from pigment producing cells. About 90% of all melanomas originate from cutaneous, but also located in the ears, gastrointestinal tract, eyes, oral and genital mucosa and leptomeninges.

As per the statistical analysis, it is the fifth leading cause of cancer death. An estimation held by the American cancer society in 2014 shows that there was more than 76,100 new cases (about 4.6 % of all newly diagnosed cancers) diagnosed. Additionally, in the same year 9710 cases of death (about 1.7% of all cancer death) were reported. There is prevalence of male over female, with higher incidence observed in age range 55-64. Men have slightly higher mortality rates than women. The percent deaths from melanoma of the skin are highest in age above 75. The death and newer incidence is found to be higher in white people. There are some predisposing factors which increases the risk of melanoma such as sun exposure, skin type, genetic factors, age skin pigmentation and social economic status.

www.gapsos.com

The drugs which are approved by FDA for the treatment of melanoma are Ipilimumab, and Nivolumab. Both of these drugs are monoclonal antibodies. Other monoclonal antibodies are currently in clinical trials like MEDI4736 and Tremelimumab. Clinical trials on vaccines and adoptive T cell are also going on like MELITAC 12.1 Peptide Vaccine, CDX-1401 and Poly-ICLC Vaccine, Dorgenmeltucel-L, CD62L+-Derived T Lymphocytes, 4-1BB tumor infiltrating cells and CD8+ antigen-specific T cells

Thus, Immunotherapy is found to be effective in the treatment of malignant melanoma and ongoing clinical trials will make this it more emerging therapy. Our success in treating malignant melanoma is increasing and advancing with the knowledge of the function of the immune system. This therapy is also functioning and showing its effectiveness against other cancers.

A skilled team of oncologists for immune based therapy and their related services are present in Global Allied Pharmaceuticals (GAP). We are working effectively to meet the unmet need for medications. 

You can contact Global Allied Pharmaceuticals for immune oncology related services and through visit on www.gapsos.com.